Cumulative incidence estimates of NRM and Kaplan–Meier survival estimates among nonmyeloablative compared with myeloablative patients with lymphoma or CLL and HCT-CI score of 0. No statistically significant differences were found between outcomes among nonmyeloablative and myeloablative patients. Further, there were no statistically significant differences between the observed outcomes among myeloablative patients and the hypothetical outcomes among nonmyeloablative patients after adjustment for pretransplantation variables including age, previous HCT, previous regimens, previous CMV infection, type and stage of malignancy, donor type, and stem-cell source. — indicates observed outcomes for myeloablative patients; , observed outcomes for nonmyeloablative patients; and …, adjusted outcomes for nonmyeloablative patients.